(13)Fmoc-Pro-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin (13) Preparation of Fmoc-Pro-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin (12)Fmoc-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin(20DMF)5203DMF3DMF2Fmoc-Pro-OH0.8gDIEA0.4mlTBTU0.56gHOBT0.2gDMF10ml1.53DMF3DMF2Fmoc-Pro-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin In the Fmoc-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin of step (12), add decapping reagent (20% DMF solution of piperidine), reacted at room temperature for 5 minutes, drained, re-added capping agent and reacted at room temperature for 20 minutes, washed 3 times with isopropanol, washed 3 times with DMF, washed 2 times with re-distilled DMF, drained, added Fmoc-Pro-OH0.8g, DIEA0.4ml, TBTU0.56g, HOBT0.2g, DMF10ml, react at room temperature for 1.5 hours, dry with a vacuum pump, wash with isopropanol for 3 times, DMF for 3 times, and redestilled DMF for washing 2 times, drained to obtain Fmoc-Pro-Pro-Pro-Gly-Lys(Boc)-Pro-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin
Clinical trial data for tirzepatide did not identify increased rates of thyroid dysfunction or autoimmune thyroid disease exacerbation, though patients with significant thyroid disease were typically excluded from pivotal trials
PMID: 35873937
Meier, [email protected] This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
